208 related articles for article (PubMed ID: 22818130)
21. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
González Larriba JL; Espinosa E; García Carbonero I; García-Donas J; López M; Meana A; Puente J; Bellmunt J
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S11-7. PubMed ID: 22674353
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapy in the treatment of metastatic renal cell cancer.
Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
24. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
26. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
27. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Bourdeanu L; Twardowski P; Pal SK
Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
Yang CH; Chuang CK; Hsieh JJ; Chang JW
Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
30. Update on novel agents in renal cell carcinoma.
Tamaskar I; Pili R
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
[TBL] [Abstract][Full Text] [Related]
31. Molecularly targeted agents for renal cell carcinoma: the next generation.
Cowey CL; Hutson TE
Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
[TBL] [Abstract][Full Text] [Related]
32. Update on the medical treatment of metastatic renal cell carcinoma.
Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
34. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
35. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
36. Optimizing treatment for metastatic renal cell carcinoma.
Patard JJ; Porta C; Wagstaff J; Gschwend JE
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1901-11. PubMed ID: 22117157
[TBL] [Abstract][Full Text] [Related]
37. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
Tan TH; Pranavan G; Haxhimolla HZ; Yip D
Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
[TBL] [Abstract][Full Text] [Related]
38. [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma].
Shinohara N
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1462-6. PubMed ID: 23064056
[TBL] [Abstract][Full Text] [Related]
39. Quality of life and supportive care for patients with metastatic renal cell carcinoma.
Lambea J; Hinojo C; Lainez N; Lázaro M; León L; Rodríguez A; Soto de Prado D; Esteban E
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S33-9. PubMed ID: 22684341
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.
Minguet J; Smith KH; Bramlage CP; Bramlage P
Cancer Chemother Pharmacol; 2015 Aug; 76(2):219-33. PubMed ID: 25963382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
